Impulse Control Disorder
10
5
5
2
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 17/100
0.0%
0 terminated out of 10 trials
100.0%
+13.5% vs benchmark
30%
3 trials in Phase 3/4
50%
1 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (10)
rTMS Over the Dorsolateral Prefrontal Cortex for the Treatment of Impulse Control Disorders in Parkinson's Disease
Efficacy of a Prediction Model-based Algorithm to PREVENT Drug-induced Impulse Control Disorders in Parkinson's Disease
Feasibility of Accelerated, Personalized rTMS as an Adjuvant for Impulse Control Disorders: a Pilot Study
Neurostimulation Versus Therapy for Problems With Emotions
STIMPulseControl Ancillary Speech Study
Frontosubthalamic Networks in Parkinson's Disease.
Remission of ICD by Switching Dopamine Agonist to Levodopa/Carbidopa
Study of the Efficacy of N-acetylcysteine (NAC) on Impulse Control Disorders
Effects of Non-invasive Brain Stimulation in Impulse Control Disorders
Naltrexone for Impulse Control Disorders in Parkinson's Disease